PF-05280602: Phase I started

Catalyst said Pfizer began an open-label Phase I trial to evaluate single doses of 0.5, 1.5, 4.5, 9, 18 and 30 µg/kg IV PF-05280602 in about 36 adults with hemophilia A and B. The trial start and IND ...